Sriram Ryali

This profile gathers the share dealings of Sriram Ryali across 3 companies, led by Eiger BioPharmaceuticals, Inc., Codexis, Inc. and Caribou Biosciences, Inc. Over a trading history stretching from 22 April 2019 to 20 February 2026, the count stands at 11 filings.

The open-market side counts 3 purchases for €54k alongside 1 sale for €12k. Taken together, the purchases exceed the sales by €43k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 7 share grants.

The median purchase comes to €19k. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 20 February 2026, the filings show a share grant in Caribou Biosciences, Inc. The last purchase on record was published on 30 January 2025, which is 647 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.